Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00779259 · ClinicalTrials.gov registry record · Phase 1
Drug - Drug Interaction Study Between Quinine Sulfate and Theophylline
A Phase 1 study, sponsored by Mutual Pharmaceutical Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00779259 is a Phase 1 study that has completed, run by Mutual Pharmaceutical Company. The registered enrollment target is 24 participants.
The verdict
NCT00779259, a Phase 1 study, has completed, sponsored by Mutual Pharmaceutical Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
In a prior in vitro study using human hepatocytes quinine was shown to induce the activity of Cytochrome p450 CYP 1A2. The present study will evaluate the extent to which quinine sulfate-related induction of this enzyme effects the pharmacokinetics of theophylline, a sensitive probe drug for the activity of CYP 1A2. It will also evaluate the effect of single-dose theophylline on the pharmacokinetics of steady-state quinine sulfate.
Interventions
- DRUG Theophylline 300mg
- DRUG Quinine 648 mg
- DRUG Theophylline 300 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2007-08 |
| Est. Completion | 2007-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00779259
The ClinicalTrials.gov registry entry for NCT00779259 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mutual Pharmaceutical Company, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Theophylline 300mg is the first listed.
NCT00779259 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00779259 about?
NCT00779259 is a clinical study titled "Drug - Drug Interaction Study Between Quinine Sulfate and Theophylline". In a prior in vitro study using human hepatocytes quinine was shown to induce the activity of Cytochrome p450 CYP 1A2. The present study will evaluate the extent to which quinine sulfate-related induction of this enzyme effects the pharmacokinetics of theophylline, a sensitive probe drug for the act...
What is the current status of trial NCT00779259?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2007-08. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00779259?
The interventions under investigation include: Theophylline 300mg (DRUG), Quinine 648 mg (DRUG), Theophylline 300 mg (DRUG).
Who is sponsoring clinical trial NCT00779259?
This trial is sponsored by Mutual Pharmaceutical Company, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.